Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer

Regorafenib, an oral multikinase inhibitor, was approved in September 2012 by the US Food and Drug Administration for the treatment of patients with metastatic colorectal cancer progressing on standar